Investor Relations

Regenerex exists to help people solve their wound care issues beyond traditional methods. Our products can significantly contribute to our mission to accelerate the healing process in advanced wounds. We continue to innovate and bring new possibilities to the advanced wound care segment of the healthcare market. We offer quality tech driven solutions to existing problems that are developed, manufactured and sourced in the USA.

Headquarters

Investor Relations
5348 Vegas Drive, Suite 177
Las Vegas, NV 89108

877-761-RGPX (7479)

Investor information line

(305) 927-5191

Transfer agent

Pacific Stock Transfer
6725 Via Austi Pkwy, Suite 300
Las Vegas, NV 89119

Phone: (702) 361-3033

http://pacificstocktransfer.com/

Cusip: 713468106

Auditors

Michael L. McKennon
dbbmckennon
Certified Public Accountants
Registered Firm – PCAOB
20321 SW Birch Street, Suite 200
Newport Beach, California 92660

Safe Harbor & Disclaimer

The information provided on this website, other than historical information, may include forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance and availability of new products and services, in addition to: the nonexclusive and terminable-at-will nature of reseller agreements with manufacturers; rapid technological change affecting products and services; the impact of competitive products and services, as well as competition from other resellers and service providers; possible delays in the launch of new products; and the availability of sufficient financial resources to enable the Company to expand its operations and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission (SEC). Regenerex Pharma, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are urged to see Regenerex Pharma, Inc. filings with the SEC for current information concerning the Company.